TriangleNCT00865969 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 24 months
What was measured
Overall Survival was the time from first administration of study treatment until the date of death.
Analysis population: Efficacy Analysis Dataset included participants who received at least 1 dose of belinostat and had a confirmed PTCL diagnosis.
Groups in this outcome
Belinostat
Belinostat 1000 mg/m\^2 administered as a 30 minute IV infusion on Days 1-5 of every 3-week cycle until disease progression or unmanageable treatment-related toxicities.
| Group | Source count |
|---|---|
| Belinostat | 120 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Belinostat | 7.9 | Not reported | 6.1 | 13.9 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 6.1
- upper Limit
- 13.9
- value
- 7.9
- denoms
- counts
- group Id
- OG000
- value
- 120
- units
- Participants
- description
- Overall Survival was the time from first administration of study treatment until the date of death.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Belinostat 1000 mg/m\^2 administered as a 30 minute IV infusion on Days 1-5 of every 3-week cycle until disease progression or unmanageable treatment-related toxicities.
- id
- OG000
- title
- Belinostat
- param Type
- MEDIAN
- population Description
- Efficacy Analysis Dataset included participants who received at least 1 dose of belinostat and had a confirmed PTCL diagnosis.
- reporting Status
- POSTED
- time Frame
- 24 months
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice